



CTM BOARD

**HIGHLIGHT REPORT – PLANNING, PERFORMANCE & FINANCE
COMMITTEE**

DATE OF MEETING	30 th March 2023
PUBLIC OR PRIVATE REPORT	Public
IF PRIVATE PLEASE INDICATE REASON	Not Applicable - Public Report
PREPARED BY	Kathrine Davies, Corporate Governance Manager
PRESENTED BY	Mel Jehu, Independent Member (Committee Chair)
EXECUTIVE SPONSOR APPROVED	Executive Director of Strategy and Transformation, Chief Operating Officer, Director of Finance
REPORT PURPOSE	FOR NOTING

ACRONYMS

IMTP	Integrated Medium Term Plan
ILG	Integrated Locality Groups
PPF	Planning, Performance & Finance

1. INTRODUCTION

- 1.1 This paper had been prepared to provide the Board with details of the key issues considered by the Planning, Performance & Finance Committee which took place on 28th February 2023.

- 1.2 Key highlights from the meeting are contained in section 2.
- 1.3 The Board are requested to **NOTE** the contents of the report and actions being taken.

2. PURPOSE OF THE PLANNING, PERFORMANCE & FINANCE COMMITTEE

The Committee will allow appropriate scrutiny and review to a level of depth and detail not possible in Board meetings in respect of planning, performance and finance. The Committee will ensure that evidence based and timely interventions are implemented to drive forward improved performance thereby allowing the Health Board to achieve the requirements and standards determined for the NHS in Wales, and as outlined within the Board's 3 Year Integrated Medium Term Plan.

3. HIGHLIGHT REPORT

ALERT / ESCALATE	<ul style="list-style-type: none"> A report was received at the 'private' In Committee meeting on the All Wales/Regional Business Case Activity. The Committee noted updates on the New Velindre Cancer Centre (nVCC) Full Business Case and the LINC Programme and Agreed to further receive them at the Extra Ordinary Planning, Performance & Finance Meeting to be held on the 22nd March 2023 for further consideration ahead of the nVCC Full Business Case being received by Board in March 2023. The Month 10 Finance report was received. Members noted that at M10 the Health Board were reporting that the forecast Core plan recurrent deficit had deteriorated to £60.9m (M9: £53.9m). The estimated financial challenge going into 2023/24 was noted as £88.7m at the time of the report. This estimate would continue be reviewed and updated as part of the Integrated Medium Term Plan (IMTP) planning process for 2023/24.
ADVISE	<ul style="list-style-type: none"> The Committee received the Organisational Risk Register and reviewed the Planning, Performance & Finance risks, noting the updates in terms of the mitigating action identified within the report.

	<ul style="list-style-type: none"> • The Committee received and noted the Month 10 Financial Performance of the individual Care Groups and Directorates. • The Committee received and noted a verbal update on progress of the CTM Strategy 2030. • A report was received on the NHS Wales Shared Services Partnership (NWSSP) Energy Procurement Proposal. The Committee Agreed to Endorse for Board Approval the proposed approach which included: <ul style="list-style-type: none"> - The revised governance group arrangements; and - The proposed new Energy Procurement contractual arrangements with Crown Commercial Services.
<p>ASSURE</p>	<ul style="list-style-type: none"> • A detailed review of the Integrated Performance Dashboard was undertaken with particular focus and scrutiny in the following areas: <ul style="list-style-type: none"> - Stoke Performance - Neurodevelopment Services - Mental Health • The Committee received a Presentation on Targeted Intervention and Improving Care and the Delivery of the Planned Care and Cancer Recovery Programme. The Committee noted the overall progress, challenges, risks and operational schemes in relation to Targeted Intervention and the Elective Recovery Portfolio of work. • A report was received on the progress of Sepsis Compliance. The Committee noted the progress made against the governance and activity in relation to the recognition, escalation and early treatment of Sepsis and the ongoing approach to improving Sepsis recognition and treatment. • A Presentation was received on the Integrated Medium Term Plan (IMTP) for 2023-26. The Committee noted that the Health Board would not be in



	<p>a position to submit a balanced plan and an 'Accountable Officer' letter had been submitted to Welsh Government outlining this position. The Committee noted that an Extra Ordinary Meeting of the Committee has been scheduled for the 22nd March 2023 where the final IMTP would be considered for Submission to the Health Board Meeting on the 30th March 2023.</p> <ul style="list-style-type: none">• A report was received at the 'private' In Committee session on the Regional Ophthalmology Strategy. The Committee noted the report and Endorsed for Board Approval the preferred option 3b.
INFORM	<ul style="list-style-type: none">• The Committee received for information the Monthly Monitoring Returns to Welsh Government for Months 9 and 10.• The Committee received and approved the Annual Cycle of Business for 2023-24.• A report was received and noted on the Spinal Services Operational Delivery Network.
APPENDICES	NOT APPLICABLE